Citation

Turdi H, Chao H, Hangeland JJ, Ahmad S, Meng W, Brigance R, Zhao G, Wang W, Moore F, Ye XY, Mathur A, Hou X, Kempson J, Wu DR, Li YX, Azzara AV, Ma Z, Chu CH, Chen L, Cullen MJ, Rooney S, Harvey S, Kopcho L, Panemangelor R, Abell L, O'Malley K, Keim WJ, Dierks E, Chang S, Foster K, Apedo A, Harden D, Dabros M, Gao Q, Pelleymounter MA, Whaley JM, Robl JA, Cheng D, Lawrence RM, Devasthale P.: Screening Hit to Clinical Candidate: Discovery of BMS-963272, a Potent, Selective MGAT2 Inhibitor for the Treatment of Metabolic Disorders. J Med Chem, Volume 64 (19), 2021

Authors

Abell L, Ahmad S, Apedo A, Azzara AV, Brigance R, Chang S, Chao H, Chen L, Cheng D, Chu CH, Cullen MJ, Dabros M, Devasthale P., Dierks E, Foster K, Gao Q, Hangeland JJ, Harden D, Harvey S, Hou X, Keim WJ, Kempson J, Kopcho L, Lawrence RM, Li YX, Ma Z, Mathur A, Meng W, Moore F, O'Malley K, Panemangelor R, Pelleymounter MA, Robl JA, Rooney S, Turdi H, Wang W, Whaley JM, Wu DR, Ye XY, Zhao G

Journal

J Med Chem

Year

2021

DOI

10.1021/acs.jmedchem.1c01356

PubMed

34613725

Machine-readable

REST APIRDF